← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Sarc
Ann Arbor, MI
$18,895,786
Total funding
15
Grants
Funding over time
peak $5.4M · FY2010–25$10M$7.5M$5M$2.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,968,331 · 11
DOD$5,927,455 · 4
By mechanism
U54$10,959,500 · 10
—$5,927,455 · 4
U01$2,008,831 · 1
Investigators at Sarc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A PHASE 2 TRIAL OF NAB-SIROLIMUS IN PATIENTS WITH PROGRESSING OR SYMPTOMATIC EPITHELIOID HEMANGIOENDOTHELIOMA$3,238,909
· FY2025 · Defense Health Agency
SARC Sarcoma SPORE$2,300,000
U54 · FY2012 · CA
SARC Sarcoma SPORE$2,185,000
U54 · FY2015 · CA
SARC Sarcoma SPORE$2,162,001
U54 · FY2014 · CA
SARC Sarcoma SPORE$2,161,999
U54 · FY2016 · CA
SARC Sarcoma SPORE$2,150,500
U54 · FY2013 · CA
PHASE I/II TRIAL OF AN HSP90 INHIBITOR IN COMBINATION WITH AN MTOR INHIBITOR FOR PATIENTS WITH REFRACTORY MALIGNANT PERIPHERAL NERVE SHEATH TUMORS$1,124,998
· FY2013 · Department of Defense
ACCELERATED CLINICAL DEVELOPMENT OF RATIONAL THERAPIES FOR MALIGNANT PERIPHERAL...$975,778
· FY2017 · Defense Health Agency
PHASE 2 STUDY: RAD001 WITH AND WITHOUT BEVACIZUMAB IN SPORADIC AND NEUROFIBROMATOSIS TYPE 1-RELATED REFRACTORY MALIGNANT PERIPHERAL NERVE SHEATH TUMO$587,770
· FY2010 · Department of Defense
A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma$571,948
U01 · FY2022 · CA
A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma$494,871
U01 · FY2020 · CA
A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma$473,617
U01 · FY2019 · CA
A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma$357,335
U01 · FY2021 · CA
Administration, Evaluation and Planning$298,636
U54 · FY2015 · CA
Tissue and Pathology Resources$287,859
U54 · FY2012 · CA
Administration, Evaluation and Planning$287,215
U54 · FY2012 · CA
Development of quantitative imaging biomarkers for assessing response to sarcoma$278,853
U54 · FY2012 · CA
Tissue and Pathology Resources$276,533
U54 · FY2014 · CA
Administration, Evaluation and Planning$275,887
U54 · FY2014 · CA
Tissue and Pathology Resources$274,404
U54 · FY2013 · CA